financial guidance

The index outperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index in the first half of the year.

Because of COVID-19, the San Diego-based firm said it was unable to ship new instruments and many users were unable to operate their existing ones.

The firm withdrew its 2020 revenue guidance and missed Wall Street estimates for both revenues and earnings.

The Pleasanton, California-based firm reported $71.9 million in revenues but missed the consensus Wall Street estimates for quarterly revenues as well as loss per share.

Increased revenues in the company's life science segment due to demand for its COVID-19-related products drove Meridian's overall growth.

The synthetic biology firm had total revenues of $19.3 million and withdrew its financial guidance for fiscal year 2020 citing uncertainty caused by COVID-19.

The firm said international sales of its OraQuick HIV products increased 74 percent year over year, driven by sales of its OraQuick HIV Self-Test.

The company's revenue growth was driven by increasing sales of its ePlex molecular diagnostics analyzer, which now has a SARS-CoV-2 test.

The firm's first quarter molecular diagnostics revenues were up 28 percent over Q1 2019 to $45.2 million.

Fulgent saw a 75 percent increase year over year in billable tests, leading to revenues of $7.8 million. It also withdrew its 2020 full-year revenue guidance.